Unknown

Dataset Information

0

Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer.

ABSTRACT:

SUBMITTER: Tanaka S 

PROVIDER: S-EPMC6987352 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Erlotinib as standard adjuvant therapy for resectable <i>EGFR</i> mutation-positive non-small cell lung cancer.

Tanaka Satomi S   Uchino Junji J  

Translational lung cancer research 20191201 Suppl 4

Similar Datasets

Unknown Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine.
| S-EPMC5906233 | biostudies-literature
Unknown Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.
| S-EPMC5858502 | biostudies-literature
Unknown Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) <i>EGFR</i> Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study.
| S-EPMC6369937 | biostudies-literature
Unknown Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer.
| S-EPMC10175038 | biostudies-literature
Unknown Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer.
| S-EPMC10169948 | biostudies-literature
Unknown Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib.
| S-EPMC5070235 | biostudies-literature
Unknown Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
| S-EPMC7226294 | biostudies-literature
Unknown Targeting PKCι-PAK1 in EGFR-mutation positive non-small cell lung cancer.
| S-EPMC6835115 | biostudies-literature
Unknown Optimizing adjuvant therapy in <i>EGFR</i>-mutated non-small cell lung cancer.
| S-EPMC7791205 | biostudies-literature
Unknown Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients.
| S-EPMC4633116 | biostudies-literature